EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients

Rick B Vega, Gavin O'Mahony iD, April M Barbour, Hongtao Yu iD, Jane Knöchel, Johan Brengdahl, Thomas Hochdörfer iD, Linnéa Bergenholm iD, Eva Töppner Carlsson, Andrea Ahnmark, Christina Rye Underwood iD, Anna Rudvik und 17 weitere

Circulation · 23.06.2026 · 153 (25) · 1999-2010

DOI: 10.1161/circulationaha.125.075973 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 23.06.2026. Verfasst von Rick B Vega und 28 weiteren Autor:innen. Beteiligte Einrichtung: Translational Science and Clinical Development, Cardiovascular, Renal and Metabolism (R.B.V.). Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Hypercholesterolemia, Anticholesteremic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective therapy for reducing low-density lipoprotein (LDL) cholesterol (LDL-C) in adults with hyperlipidemia, including heterozygous familial hypercholesterolemia, thereby lowering cardiovascular risk. Current PCSK9 inhibitors are injectable therapies; no oral small-molecule PCSK9 inhibitor has yet been approved. METHODS: Laroprovstat (AZD0780) is a novel small-molecule identified through structure-based design that binds to the PCSK9 C-terminal domain. The effects of laroprovstat on LDL receptor expression and LDL-C levels were assessed in vitro and in mice expressing human PCSK9 . Safety, tolerability, and pharmacokinetic and pharmacodynamic properties of laroprovstat were assessed in healthy participants with LDL-C ≥70 and ≤190 mg/dL after single ascending doses. Laroprovstat was also assessed in participants with LDL-C ≥100 and ≤190 mg/dL at doses of 1 mg or 30 mg versus placebo administered once daily for 28 days after a rosuvastatin 20 mg run-in treatment period. RESULTS: Laroprovstat does not inhibit the PCSK9–LDL receptor interaction but stabilizes the PCSK9 C-terminal domain, preventing lysosomal trafficking and degradation of LDL receptor. Laroprovstat increased LDL receptor expression and reduced LDL-C levels in mice expressing human PCSK9 . Laroprovstat displayed dose-proportional pharmacokinetics and a half-life suitable for once-daily dosing (≈40 hours). There was no clinically meaningful change in exposure when dosed with a high-fat meal compared with the fasted state (area under the plasma concentration-time curve inf and C max geometric mean reduction of 1.15 [90% CI, 1.11–1.19] and 1.06 [90% CI, 1.00–1.13], respectively). After a rosuvastatin 20 mg 3-week run-in treatment period, laroprovstat 1 and 30 mg reduced LDL-C by 29% (95% CI, 18%–38%) and 51% (95% CI, 44%–58%) compared with baseline. Combined rosuvastatin and laroprovstat treatment resulted in a total approximate reduction in LDL-C of 70% and 80% for laroprovstat 1 and 30 mg, respectively. CONCLUSIONS: Laroprovstat was well tolerated with no safety findings of concern and may be dosed with or without food. In treatment-naïve participants with hypercholesterolemia, combined rosuvastatin 20 mg and laroprovstat 30 mg treatment led to an 80% LDL-C reduction, supporting further development of laroprovstat as the first oral small-molecule PCSK9 inhibitor in patients with hypercholesterolemia. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05384262.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsHypercholesterolemiaAnticholesteremic AgentsHumansProprotein Convertase 9AnimalsMaleAdultFemaleMiddle AgedCholesterol, LDLMiceReceptors, LDLAdministration, OralSingle-Blind MethodYoung Adult

Stichwörter der Autor:innen

PCSK9 inhibitorsclinical trial, phase 1hypercholesterolemia

Substanzen

PCSK9 InhibitorsProprotein Convertase 9PCSK9 protein, humanCholesterol, LDLReceptors, LDLAnticholesteremic Agents

Autor:innen und Institutionen

  • Translational Science and Clinical Development, Cardiovascular, Renal and Metabolism (R.B.V.).
  • Biopharma Chemistry, Discovery Sciences (G.O.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (A.M.B., H.Y.), AstraZeneca, Gaithersburg, MD.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences (J.K.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (J.B.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Mechanistic Biology and Profiling, Discovery Sciences (T.H.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Gavin O'Mahony, Hongtao Yu, Thomas Hochdörfer, Linnéa Bergenholm, Christina Rye Underwood, Aspen Gutgsell, Pavlo Garkaviy, Tasso Miliotis, Maria Ryaboshapkina, Andreas Hober, Virendar Kaushik, Stefan Geschwindner, Daniel Lindén, Jaya B Rosenmeier

Zitieren

APA

Vega, R. B., O'Mahony, G., Barbour, A. M., Yu, H., Knöchel, J., Brengdahl, J., Hochdörfer, T., Bergenholm, L., Töppner Carlsson, E., Ahnmark, A., Underwood, C. R., Rudvik, A., Carter, D., Laru, J., Gutgsell, A., Twaddle, L., Garkaviy, P., Bogstedt, A., Hurt-Camejo, E., …, & Rosenmeier, J. B. (2026). Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. Circulation, 153(25), 1999-2010. https://doi.org/10.1161/circulationaha.125.075973

Vancouver

Vega RB, O'Mahony G, Barbour AM, Yu H, Knöchel J, Brengdahl J, et al. Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. Circulation. 2026;153(25):1999-2010. doi:10.1161/circulationaha.125.075973

BibTeX
@article{Vega2026,
  author = {Vega, Rick B and O'Mahony, Gavin and Barbour, April M and Yu, Hongtao and Knöchel, Jane and Brengdahl, Johan and Hochdörfer, Thomas and Bergenholm, Linnéa and Töppner Carlsson, Eva and Ahnmark, Andrea and Underwood, Christina Rye and Rudvik, Anna and Carter, Debra and Laru, Johanna and Gutgsell, Aspen and Twaddle, Lee and Garkaviy, Pavlo and Bogstedt, Anna and Hurt-Camejo, Eva and Miliotis, Tasso and Ryaboshapkina, Maria and Hober, Andreas and Hubbard, Brian and Serrano-Wu, Michael and Kaushik, Virendar and Geschwindner, Stefan and McCarthy, Michael C and Lindén, Daniel and Rosenmeier, Jaya B},
  title = {Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients},
  journal = {Circulation},
  year = {2026},
  volume = {153},
  number = {25},
  pages = {1999--2010},
  doi = {10.1161/circulationaha.125.075973}
}
Kostenlos starten →